Mazowiecki Szpital Brodnowski Sp. z o.o.

The Neurology Clinic at Mazowiecki Szpital Brodnowski is conducting studies aimed at improving outcomes after myocardial infarction and in patients with acute heart failure. Trials evaluate novel agents such as dapagliflozin and intravenous iron therapy to reduce mortality, hospital readmission, and enhance quality of life.

• Recent myocardial infarction
• Acute heart failure
• Venous thromboembolism
• Iron deficiency after MI

These investigations reflect the site’s commitment to advancing cardiovascular care alongside its neurological focus.

Research at the clinic includes trials in ovarian cancer and related gynecologic malignancies, assessing maintenance strategies with agents like rucaparib and dose‑equivalence of bevacizumab. The goal is to prolong progression‑free survival and improve patient outcomes after frontline chemotherapy.

• Ovarian epithelial cancer
• Fallopian tube cancer
• Peritoneal carcinoma
• High‑grade serous ovarian cancer

The oncology program integrates targeted therapies with immunotherapy to address high‑risk disease.

The site evaluates new treatments for endocrine disorders such as acromegaly and Cushing's disease. One study investigates the effect of Lu AG13909 on hormone levels, safety, and tolerability, aiming to provide better disease control for patients with these rare conditions.

• Acromegaly
• Cushing's disease

These trials support the development of therapies that normalize hormonal excess.

A broad portfolio of neurological studies targets movement and neurodegenerative disorders. Ongoing work in Parkinson's disease explores disease‑modifying antibodies, while gene‑therapy approaches are tested in Huntington's disease. Trials also address Frontotemporal dementia with progranulin mutations and assess slowing of disability in progressive supranuclear palsy.

• Parkinson's disease
• Huntington's disease
• Frontotemporal dementia
• Progressive supranuclear palsy

Innovative delivery methods, including intracerebral infusion, are being evaluated to enhance therapeutic efficacy.

The clinic’s research includes hereditary neurodegenerative conditions. Studies focus on disorders caused by a genetic mutation, such as progranulin‑related frontotemporal dementia and the inherited expansion seen in Huntington’s disease, aiming to modify disease progression early in the disease course.

• Huntington's disease
• Frontotemporal dementia with progranulin mutation

These efforts highlight the site’s dedication to precision medicine for inherited neurological disorders.

While the primary focus is neurological, the institution is preparing exploratory studies on bacterial infections and fungal diseases, evaluating safety of novel antimicrobial agents in hospitalized patients.

• Exploratory antimicrobial safety study
• Fungal infection monitoring trial

Future protocols may integrate infection control with neurology patient management.

The research environment at the clinic supports multidisciplinary research, allowing investigators to cross traditional therapeutic boundaries and address complex patient needs.

• Cardiovascular
• Oncology
• Neurology
• Endocrinology

This flexibility enables the site to respond quickly to emerging scientific opportunities.